TABLE 2.
8-Week Probability and Cost Parameters for the Markov Model of Therapies for Patients Who Discontinue IFX
| Parameter | Value | Source |
|---|---|---|
| Adalimumab | ||
| Probability of initial response | 0.52 | 29 |
| Probability of maintaining response | 0.95 | 30 |
| Cost of first 8-week period | $7932.488 | 12 |
| Cost of subsequent 8-week periods | $3345.956 | 12 |
| Certolizumab | ||
| Probability of initial response | 0.64 | 31 |
| Probability of maintaining response | 0.93 | 31 |
| Cost of first 8-week period | $9801.52 | 12 |
| Cost of subsequent 8-week periods | $5684.54 | 12 |
| Vedolizumab | ||
| Probability of initial response | 0.47 | 32 |
| Probability of maintaining response | 0.88 | 33 |
| Cost of first 8-week period | $7649.416 | 12 |
| Cost of subsequent 8-week periods | $2170.762 | 12 |
| Ustekinumab | ||
| Probability of initial response | 0.38 | 34 |
| Probability of maintaining response | 0.94 | 34 |
| Cost of first 8-week period | $3470.35 | 12 |
| Cost of subsequent 8-week periods | $7140.30 | 12 |
| Surgery | ||
| Probability of surgical death | 0.0015 | 10 |
| Probability of surgical complicationsa | 0.21 | 11 |
| If no long-term complications, probability of sustained response following surgery | 0.76 | 35 |
| Cost of surgery (one-time) | $11,613.65 | 14, 15 |
| Cost of surgical complications | $27,205.22 | 14, 15 |
| Health care costs for those with a sustained response following surgery | $21.98 | 14, 15 |
| Health care costs for those without sustained response following surgery | $1954.75 | 14, 15 |
| Utility weight of surgical complications | 0.15 | 17 |
aSurgical complications combined into immediate and delayed